Saad Z. Usmani, M.D on FDA approval of DARZALEX FASPRO @LevineCancer

Saad Z. Usmani, M.D of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab in the treatment of patients with MM.

Read here: https://www.prnewswire.com/news-releases/us-food-and-drug-administration-approves-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-a-new-subcutaneous-formulation-of-daratumumab-in-the-treatment-of-patients-with-multiple-myeloma-301051154.html